

PRECEPTORSHIP PROGRAMME

Metastatic Bladder and Kidney Cancer

Multidisciplinary management,
standards of care, therapeutic targets
and future perspectives

LUGANO
SWITZERLAND

11-12 JULY 2022

Co-Chairs

Laurence Albiges, France

Viktor Grünwald, Germany

ESMO PRECEPTORSHIP PROGRAMME METASTATIC BLADDER AND KIDNEY CANCER

Multidisciplinary management, standards of care,
therapeutic targets and future perspectives

Lugano, Switzerland
11-12 July 2022

CO-CHAIRS: Laurence Albiges, France
Viktor Grünwald, Germany

SPEAKERS: Axel Bex, United Kingdom
Maria De Santis, Germany
Yohann Loriot, France
Holger Moch, Switzerland
Camillo Porta, Italy
Thomas Powles, United Kingdom
Morgan Roupret, France
Manuela Schmidinger, Austria
Cristina Suarez, Spain
Gunhild Von Amsberg, Germany

LEARNING OBJECTIVES

- To learn about fundamentals of molecular pathology and diagnosis as contributing factors to heterogeneity in bladder and kidney cancer
- To understand essentials in the assessment and multidisciplinary treatment of bladder and kidney cancer
- To learn about advances in treatment and novel targets in bladder and kidney cancer

ACCREDITATION

The programme of this event has been accredited with **10 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



and

Supported by an **independent educational grant** from **Merck Healthcare KGaA**, Darmstadt, Germany

ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org



Monday, 11 July 2022

09:00-09:15 15'	Opening and welcome	
15'	Welcome from ESMO - Objectives and scientific introduction	Viktor Grünwald, DE
09:15-10:10 55'	SESSION 1 Pathology and molecular pathology	Chair: Laurence Albiges, FR
20'	Bladder cancer	Holger Moch, CH
20'	Kidney cancer	Holger Moch, CH
15'	Discussion	Faculty
10:10-10:40	Coffee break	
10:40-12:35 115'	SESSION 2 Systemic treatment in urothelial carcinoma (UC)	Chair: Thomas Powles, UK
15'	Peri-operative Chemotherapy in MIBC and UTUC	Gunhild Von Amsberg, DE
20'	L1 metastatic UC	Thomas Powles, UK
20'	2 nd line and sequence	Maria De Santis, DE
15'	New agents	Yohann Lorient, FR
45'	Participants clinical case discussion (3x15')	Faculty
12:35-13:35	Lunch	
13:35-15:10 95'	SESSION 3 Systemic treatment in renal cell cancer (RCC)	Chair: Laurence Albiges, FR
20'	Peri-operative: Neoadjuvant and adjuvant in RCC	Axel Bex, UK
20'	1 st line treatment for clear-cell mRCC	Camillo Porta, IT
20'	2 nd line treatment for cc mRCC and new agents	Manuela Schmidinger, AT
20'	Treatment for non-clear-cell mRCC	Cristina Suarez, ES
15'	Discussion	Faculty
15:10-15:45 35'	SESSION 4 Debate of the day	Chair: Laurence Albiges, FR
20'	Factors to inform L1 decision: - IO-TKI - IO-IO	Viktor Grünwald, DE Laurence Albiges, FR
15'	Discussion	Faculty
15:45-16:15	Coffee break	

16:15-17:30 75'	SESSION 5 NMIBC and peri-operative treatment in localized MIBC	Chair: Maria De Santis, DE
20'	Systemic treatment for NMIBC - Where do we stand?	Morgan Roupret, FR
20'	Neoadjuvant IO based treatment in MIBC	Yohann Lorient, FR
20'	Adjuvant IO treatment in MIBC: The PRO's and CON's	Thomas Powles, UK
15'	Discussion	Faculty
19:00	Dinner	

Tuesday, 12 July 2022

09:00-09:35 35'	SESSION 6 Biomarker use to inform treatment strategy	Chair: Laurence Albiges, FR
20'	Bladder cancer	Thomas Powles, UK
15'	Discussion	Faculty

09:35-10:35 60'	SESSION 7 Clinical case in metastatic RCC	Chair: Laurence Albiges, FR
45'	Participants clinical case discussion (3x15')	Faculty
15'	Discussion	Faculty

10:35-11:05	Coffee break	
--------------------	---------------------	--

11:05-12:50 105'	SESSION 8 Side effects Management	Chair: Laurence Albiges, FR
15'	ADC side effect management	Yohann Lorient, FR
15'	IO- VEGFR TKI	Gunhild Von Amsberg, DE
15'	IO/IO and IO single agent	Camillo Porta, IT
15'	Discussion	Faculty
45'	Participants clinical case discussion (3x15')	Faculty

12:50-13:00 10'	Conclusion and farewell	Laurence Albiges, FR
---------------------------	--------------------------------	-----------------------------

13:00-14:00	Lunch	
--------------------	--------------	--

Note: Each 15 minutes slot for clinical case discussion includes 7' case presentation and 8' Q&A / panel discussion